New treatment options for HCV infection with Direct-Acting Antivirals (DAAs) increased SVR rate in treated patients but on the other hand drew attention to the problem of HCV drug resistance. Drug-resistant HCV mutants are present in all infected patients even before the treatment initiation and their number grows significantly over the first few days of DAAs therapy. But HCV has no known genetic form of intra-cellular persistence (does not integrate with host's genome and cannot produce episomal forms) which enables its total eradication. It is likely that the effective interferon-free, based on all-oral DAAs drug combination will be available within the next few years. This paper reviews HCV resistance mechanisms and their significance in treatment. I also presents results of recent DAAs trials.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.
J Virus Erad
December 2024
Vancouver Infectious Diseases Center, Vancouver, British Columbia, Canada.
Background: Several clinical trials, including the recently published the GRAND PLAN study from Vancouver Infectious Diseases Center (VIDC), have demonstrated the efficacy of hepatitis C (HCV) therapy among active drug users, including those facing significant addiction-related and social challenges. In the GRAND PLAN, we documented sustained virological response post-treatment Week12 (SVR12) in 108/117 (92.3 %) individuals (108/111 (mITT) or 97.
View Article and Find Full Text PDFSynthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides.
Molecules
December 2024
Institute of Organic and Analytical Chemistry (ICOA UMR 7311), CNRS, University of Orleans, F-45067 Orléans, France.
The emergence of RNA viruses driven by global population growth and international trade highlights the urgent need for effective antiviral agents that can inhibit viral replication. Nucleoside analogs, which mimic natural nucleotides, have shown promise in targeting RNA-dependent RNA polymerases (RdRps). Starting from protected 5-iodouridine, we report the synthesis of -substituted-(1,3-diyne)-uridines nucleosides and their phosphoramidate prodrugs.
View Article and Find Full Text PDFLiving Donor Liver Transplantation Using Right Posterior Section Graft in a Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patient With Hemophilia: A Case Report.
Transplant Proc
January 2025
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address:
Background: Liver transplantation is an important treatment option for liver cirrhosis in patients with HIV/HCV coinfection. In Japan, the limited number of deceased donors may force the selection of living donor liver transplantation. Appropriate graft selection is the key to success.
View Article and Find Full Text PDFOn the steroids extracted from soft corals against the NS3/4A protease of hepatitis C virus.
J Mol Graph Model
December 2024
Faculty of Chemistry and Center for Computational Science, Hanoi National University of Education, Hanoi, Viet Nam; Institute of Natural Sciences, Hanoi National University of Education, Hanoi, Viet Nam.
The Hepatitis C virus (HCV) causes a variety of liver diseases, making it a global health issue that affects millions of people in the world. The NS3/4A protease has been considered a common target for anti-HCV treatments using direct-acting antiviral agents and their derivatives. Of the natural products that have been proposed for novel therapeutic product alternatives, the soft coral compounds are found to contain steroids with various bioactive properties for effective HCV treatments.
View Article and Find Full Text PDFCardiovascular disease and its risk factors among people living with HIV: A systematic review and meta-analysis.
J Infect Public Health
January 2025
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No.38, Xueyuan Road, Haidian District, Beijing 100191, China; Institute for Global Health and Development, Peking University, No.5, Yiheyuan Road, Haidian District, Beijing 100871, China; Global Center for Infectious Disease and Policy Research & Global Health and Infectious Diseases Group, Peking University, No.38, Xueyuan Road, Haidian District, Beijing 100191, China; Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, No.38, Xueyuan Road, Haidian District, Beijing 100191, China. Electronic address:
This meta-analysis aimed to quantify the latest cardiovascular disease (CVD) incidence rate and assess the impact of risk factors among people living with HIV (PLWH). We searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for studies published up to September 14, 2023. To evaluate effect sizes, we employed multilevel (three-level) random-effects meta-analyses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!